早期透明细胞卵巢癌辅助铂类化疗三个周期与六个周期的比较——一项多机构队列研究
Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
作者信息
Prendergast Emily N, Holzapfel Marie, Mueller Jennifer J, Leitao Mario M, Gunderson Camille C, Moore Kathleen N, Erickson Britt K, Leath Charles A, Diaz Moore Elena S, Cohen Joshua G, Walsh Christine S
机构信息
Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Gynecol Oncol. 2017 Feb;144(2):274-278. doi: 10.1016/j.ygyno.2016.12.004. Epub 2016 Dec 12.
OBJECTIVES
To determine if 6 versus 3cycles of adjuvant platinum-based chemotherapy with or without taxane impacts survival in early stage ovarian clear cell carcinoma (OCCC).
METHODS
We retrospectively identified all cases of stage I and II OCCC treated at 5 institutions from January 1994 through December 2011. Patients were divided into 2 groups: those who received 3 versus 6cycles of adjuvant chemotherapy. Our cohort consisted of 210 patients with stage IA-II disease, 116 of whom underwent full surgical staging. Cox proportional hazards regression and Kaplan-Meier analyses were performed to evaluate progression-free (PFS) and overall survival (OS) between groups.
RESULTS
Among 210 eligible patients, the median age was 53years (range 30-88). The majority of patients were Caucasian (83.8%). All patients received adjuvant chemotherapy with 90% receiving carboplatin and paclitaxel. Thirty-eight (18.1%) patients received 3cycles, and 172 (81.9%) patients received 6cycles of adjuvant treatment. Recurrence rate was comparable between groups (18.4% vs. 27.3% for 3 vs. 6cycles, p=0.4). There was no impact of 3 versus 6cycles of chemotherapy on PFS (hazard ratio [HR] 1.4; 95% confidence interval [CI] 0.63-3.12, p=0.4) or OS (HR 1.65; 95% CI 0.59-4.65, p=0.3) on univariate analysis. There was no benefit to more chemotherapy in stratified analysis by stage nor on multivariate analysis adjusting for the impact of stage. Subgroup analysis of surgically staged patients also showed no difference in survival between 3 versus 6cycles of chemotherapy.
CONCLUSIONS
Three cycles of platinum with or without taxane adjuvant chemotherapy were comparable to 6cycles with respect to recurrence and survival in patients diagnosed with early stage ovarian clear cell carcinoma in this retrospective multi-institutional cohort.
CONDENSATION
Three cycles of platinum with or without taxane adjuvant chemotherapy are comparable to 6 cycles with respect to recurrence and survival in patients diagnosed with early stage ovarian clear cell carcinoma in this retrospective multi-institutional cohort.
目的
确定含或不含紫杉烷的6周期与3周期铂类辅助化疗对早期卵巢透明细胞癌（OCCC）患者生存率的影响。
方法
我们回顾性分析了1994年1月至2011年12月期间在5家机构接受治疗的所有Ⅰ期和Ⅱ期OCCC病例。患者分为两组：接受3周期与6周期辅助化疗的患者。我们的队列包括210例IA-II期疾病患者，其中116例接受了全面的手术分期。采用Cox比例风险回归和Kaplan-Meier分析评估两组之间的无进展生存期（PFS）和总生存期（OS）。
结果
在210例符合条件的患者中，中位年龄为53岁（范围30-88岁）。大多数患者为白种人（83.8%）。所有患者均接受辅助化疗，90%接受卡铂和紫杉醇。38例（18.1%）患者接受3周期化疗，172例（81.9%）患者接受6周期辅助治疗。两组的复发率相当（3周期与6周期分别为18.4%对27.3%，p=0.4）。单因素分析显示，3周期与6周期化疗对PFS（风险比[HR]1.4；95%置信区间[CI]0.63-3.12，p=0.4）或OS（HR 1.65；95%CI 0.59-4.65，p=0.3）均无影响。在按分期进行的分层分析中，以及在调整分期影响的多因素分析中，更多周期的化疗均无益处。手术分期患者的亚组分析也显示，3周期与6周期化疗的生存率无差异。
结论
在这个回顾性多机构队列中，对于诊断为早期卵巢透明细胞癌的患者，含或不含紫杉烷的3周期铂类辅助化疗在复发和生存方面与6周期化疗相当。
总结
在这个回顾性多机构队列中，对于诊断为早期卵巢透明细胞癌的患者，含或不含紫杉烷的3周期铂类辅助化疗在复发和生存方面与6周期化疗相当。
Zotero 插件